Results 61 to 70 of about 66,826 (280)

Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes (PROs) in youth with axial juvenile spondyloarthritis (axJSpA) initiating tumor necrosis factor inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

Blue Ear Drum as an Unusual Adverse Effect of Adalimumab: A Case Report

Central Asian Journal of Medical Hypotheses and Ethics
Adalimumab has been employed for an extended period as an efficacious and secure agent for inflammatory bowel and rheumatic diseases. ABP 501 is one of the biosimilars of adalimumab and has a similar safety profile to that of the original adalimumab ...
Abdulvahap Kahveci, Murat Yaşar
doaj   +1 more source

OGFRL1 Deficiency Causes Chronic Recurrent Multifocal Osteomyelitis Via Pathologic Osteoclastogenesis, With Therapeutic Response to Tumor Necrosis Factor Inhibitor

Arthritis &Rheumatology, EarlyView.
Objective To verify the pathogenesis of the opioid growth factor receptor like‐1 (OGFRL1) loss‐of‐function variant (c.30del, p. F10Ffs*110) identified in a patient with chronic recurrent multifocal osteomyelitis (CRMO) and to investigate the underlying mechanism.
Wen Xiong, Yusha Wang, Tingyan He, Jinjian Fu, Ying Luo, Jinbo Wang, Jun Wang, Xiaomin Yu, Qing Zhou, Jun Yang   +9 more
wiley   +1 more source

Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial [PDF]

, 2017
markdownabstract__Background:__ The introduction of anti-tumor necrosis factor medications has revolutionized the treatment of psoriasis with achievement of treatment goals (Psoriasis Area and Severity Index score 75, remission) that are not usually met ...
B. A. Hutten, C. I. Busard, E. M. de Jong, E. P. Prens, J. M. van den Reek, J. S. van Bezooijen, M. B. van Doorn, P. I. Spuls, S. P. Menting   +8 more
core   +16 more sources

Consumed by Abdominal Distention

Arthritis Care &Research, EarlyView.
Abimbola Fadairo‐Azinge, James Grenert, Brian Haas, Mary Margaretten   +3 more
wiley   +1 more source

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First‐Line Therapy

Arthritis &Rheumatology, EarlyView.
Objective Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in juvenile idiopathic arthritis–associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU. Methods Retrospective multicenter study involving the rheumatology and ophthalmology units at Florence, Italy ...
Ilaria Maccora, Catherine Guly, Cinzia de Libero, Giulia Carreras, Athimalaipet V. Ramanan, Gabriele Simonini   +5 more
wiley   +1 more source

Adalimumab induced psoriasis in a Crohn’s disease patient: a case report

Journal of the Pakistan Medical Association
Adalimumab is a human monoclonal antibody that selectively targets tumour necrosis factor-alpha (TNF- Alpha), a cytokine involved in the pathogenesis of various inflammatory and autoimmune disorders.
Dhaifallah Alrakawi Alenizi
doaj   +1 more source

Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of the Phase 3, Randomized, Placebo‐Controlled SOLSTICE Study

Arthritis &Rheumatology, Accepted Article.
Objective Evaluate the efficacy and safety of guselkumab, an interleukin‐23p19‐subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor inhibitor (TNFi‐IR).
Alexis Ogdie, Joseph F Merola, Philip J Mease, Christopher T Ritchlin, Jose U Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B Gottlieb   +12 more
wiley   +1 more source

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study

Frontiers in Pharmacology, 2019
Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA).Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients.
Salvatore D'Angelo, Salvatore D'Angelo, Fabrizio Cantini, Roberta Ramonda, Luca Cantarini, Antonio Carletto, Maria Sole Chimenti, Andrea Delle Sedie, Rosario Foti, Roberto Gerli, Claudia Lomater, Ennio Lubrano, Antonio Marchesoni, Alen Zabotti, Carlo Salvarani, Carlo Salvarani, Rossana Scrivo, Raffaele Scarpa, Giuseppina Tramontano, Carlotta Nannini, Mariagrazia Lorenzin, Marta Fabbroni, Federica Martinis, Roberto Perricone, Linda Carli, Elisa Visalli, Guido Rovera, Fabio Massimo Perrotta, Luca Quartuccio, Alessio Altobelli, Luisa Costa, Laura Niccoli, Augusta Ortolan, Francesco Caso   +33 more
doaj   +1 more source

Biologic treatments in rheumatoid arthritis and juvenile idiopathic arthritis [PDF]

, 2006
A number of biological approaches to the management of inflammtory arthropathies have been explored. These include the development of IL-1 receptor antagonists and TNF antagonists. Four biological agents are currently marketed in Europe.
Borg, Andrew A.
core